Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03962543 · MORE INFO

Limitations, agreements, and source contact

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas · Source last updated 2026-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
clinical@springworkstx.com
organization
SpringWorks Therapeutics, Inc.
phone
8772794870
title
Head of Clinical Operations
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
clinical@springworkstx.com
organization
SpringWorks Therapeutics, Inc.
phone
8772794870
title
Head of Clinical Operations

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice